EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

rs10010131A in WFS1 is Associated with Elevated Serum Urea in Type 2 Diabetes Patients Treated with SGLT2 Inhibitors

Khaled Naja iD, Asma A Elashi, Laila Hedaya iD, Najeha Rizwana Anwardeen iD, Mashael Al-Shafai, Manfredi Rizzo iD, Mohamed A Elrayess

Therapeutics and Clinical Risk Management · 2026-04 · Volume 22 · 1-9

DOI: 10.2147/tcrm.s578286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutics and Clinical Risk Management, 2026-04. Verfasst von Khaled Naja und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Center, QU Health, Qatar University, Doha, Qatar. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

metforminpharmacogenomicssodium-glucose cotransporter 2 inhibitorstype 2 diabetesureawolframin

Autor:innen und Institutionen

  • Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.
  • Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • School of Medicine, Promise Department, University of Palermo, Palermo, Italy.
  • Department of Medicine, Ras Al Khaimah (RAK) Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
  • College of Medicine, QU Health, Qatar University, Doha, Qatar.

ORCID-Profile: Khaled Naja, Laila Hedaya, Najeha Rizwana Anwardeen, Manfredi Rizzo

Zitieren

APA

Naja, K., Elashi, A. A., Hedaya, L., Anwardeen, N. R., Al-Shafai, M., Rizzo, M., & Elrayess, M. A. (2026). rs10010131A in WFS1 is Associated with Elevated Serum Urea in Type 2 Diabetes Patients Treated with SGLT2 Inhibitors. Therapeutics and Clinical Risk Management, Volume 22, 1-9. https://doi.org/10.2147/tcrm.s578286

Vancouver

Naja K, Elashi AA, Hedaya L, Anwardeen NR, Al-Shafai M, Rizzo M, et al. rs10010131A in WFS1 is Associated with Elevated Serum Urea in Type 2 Diabetes Patients Treated with SGLT2 Inhibitors. Therapeutics and Clinical Risk Management. 2026;Volume 22:1-9. doi:10.2147/tcrm.s578286

BibTeX
@article{Naja2026,
  author = {Naja, Khaled and Elashi, Asma A and Hedaya, Laila and Anwardeen, Najeha Rizwana and Al-Shafai, Mashael and Rizzo, Manfredi and Elrayess, Mohamed A},
  title = {rs10010131A in WFS1 is Associated with Elevated Serum Urea in Type 2 Diabetes Patients Treated with SGLT2 Inhibitors},
  journal = {Therapeutics and Clinical Risk Management},
  year = {2026},
  volume = {Volume 22},
  pages = {1--9},
  doi = {10.2147/tcrm.s578286}
}
Kostenlos starten →